Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
17.40
-0.80 (-4.40%)
Jan 17, 2025, 4:00 PM EST - Market closed
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang Pham |
Contact Details
Address: 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 United States | |
| Phone | 904 300 0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001937993 |
| ISIN Number | US1276361086 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman and Chief Executive Officer |
| Matthew K. Szot CPA, CPA | Co-Founder and Chief Financial Officer |
| Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer |
| Jeffrey Cole | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 15, 2025 | SCHEDULE 13G/A | Filing |
| Dec 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 20, 2024 | 424B5 | Filing |
| Nov 25, 2024 | 424B3 | Prospectus |
| Nov 22, 2024 | EFFECT | Notice of Effectiveness |
| Nov 20, 2024 | UPLOAD | Filing |
| Nov 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 7, 2024 | 10-Q | Quarterly Report |